Home › Compare › MITO vs EQR

MITO vs EQR: Dividend Comparison 2026

MITO yields 625.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MITO wins by $359450.77M in total portfolio value
10 years
MITO
MITO
● Live price
625.00%
Share price
$0.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$359450.81M
Annual income
$273,399,800,572.91
Full MITO calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MITO vs EQR

📍 MITO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMITOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MITO + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MITO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MITO
Annual income on $10K today (after 15% tax)
$53,125.00/yr
After 10yr DRIP, annual income (after tax)
$232,389,830,486.97/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, MITO beats the other by $232,389,827,240.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MITO + EQR for your $10,000?

MITO: 50%EQR: 50%
100% EQR50/50100% MITO
Portfolio after 10yr
$179725.42M
Annual income
$136,699,902,196.25/yr
Blended yield
76.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MITO
Analyst Ratings
6
Buy
Consensus: Buy
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MITO buys
0
EQR buys
0
No recent congressional trades found for MITO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMITOEQR
Forward yield625.00% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$359450.81M ✓$40.5K
Annual income after 10y$273,399,800,572.91 ✓$3,819.61
Total dividends collected$352328.39M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: MITO vs EQR ($10,000, DRIP)

YearMITO PortfolioMITO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$73,200$62,500.00$11,248$547.57+$62.0K → MITO
2$505,894$427,570.09$12,701$666.53+$493.2K → MITO
3$3,302,979$2,761,671.84$14,405$814.59+$3.29M → MITO
4$20,385,527$16,851,339.68$16,413$999.84+$20.37M → MITO
5$119,012,643$97,200,129.44$18,795$1,232.92+$118.99M → MITO
6$657,683,338$530,339,810.29$21,639$1,527.95+$657.66M → MITO
7$3,442,734,786$2,739,013,613.82$25,057$1,903.80+$3442.71M → MITO
8$17,083,489,966$13,399,763,745.21$29,197$2,385.87+$17083.46M → MITO
9$80,421,501,126$62,142,166,862.30$34,250$3,008.70+$80421.47M → MITO
10$359,450,806,778$273,399,800,572.91$40,467$3,819.61+$359450.77M → MITO

MITO vs EQR: Complete Analysis 2026

MITO — Stock

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Full MITO Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MITO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MITO vs SCHDMITO vs JEPIMITO vs OMITO vs KOMITO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.